Patent 9682153 was granted and assigned to Nektar Therapeutics on June, 2017 by the United States Patent and Trademark Office.
The invention provides peptides that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the peptide not attached to the water-soluble oligomer.